Pherecydes Pharma Company Profile: Stock Performance & Earnings

Pherecydes Pharma Overview

Founded
2006

Status
Public

Employees
20

Stock Symbol
ALPHE

Share Price
$10.62
(As of Thursday Closing)

Pherecydes Pharma General Information

Description

Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. It focuses on various bacterial infections, including antibiotic-resistant infections, using phages, natural predators of bacteria that have no effect on eukaryotic cells, including human cells.

Contact Information

Website

www.pherecydes-pharma.com

Ownership Status

Publicly Held

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery

Stock Exchange

PAR

Primary Office

20 Boulevard Bénoni Goullin
44200 Nantes
France

+33 01 00 00 00 00





Pherecydes Pharma Timeline

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pherecydes Pharma Stock Performance

(As of Thursday Closing)

Stock Price	Previous Close	52 wk Range	Market Cap	Shares	Average Volume	EPS
$10.62	$10.46	$9.72 - $19.74	$61.7M	5.81M	28.2K	-$0.43

Pherecydes Pharma Financials Summary

In Thousands, USD	TTM 30-Jun-2020	FY 2019 31-Dec-2019	FY 2018 31-Dec-2018	FY 2017 31-Dec-2017
Revenue	1,553	2,532	3	360
EBITDA	(3,715)	(2,747)	(3,692)	(2,167)
Net Income	(2,453)	(1,368)	(2,855)	(1,729)
Total Assets	6,844	7,837	7,044	10,383
Total Debt	1	1,342	929	90

Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pherecydes Pharma Valuation & Funding

Deal Type	Date	Amount	Valuation/ EBITDA	Post-Val	Status	Debt

This information is available in the PitchBook Platform. To explore Pherecydes Pharma‘s full profile, request access.

Request a free trial

Pherecydes Pharma Comparisons

Description

Primary
Industry

HQ Location

Employees

Total Raised

Post Valuation

Last Financing Details

Pherecydes Pharma develops phage-based therapeutic solutions for the treatment of bacterial infections. It focuses on va

Biotechnology

Nantes, France

20 As of 2021

0000

00.00 0000-00-00

00000000 0000

00000000

smod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerc

0000000000000

South San Francisco, CA

00 As of 0000

000.00

00.00 0000-00-00

00000000000 000.00

0000000

it, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis

0000 000000000

Cambridge, MA

00 As of 0000

00000

00000000000 00000

Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pherecydes Pharma Competitors (16)

Company Name	Financing Status	Location	Employees	Total Raised	Last Financing Date/Type	Last Financing Amount
AvidBiotics	Venture Capital-Backed	South San Francisco, CA	00	000.00	00000000000	000.00
0000000 0000000000	Venture Capital-Backed	Cambridge, MA	00	00000	00000000000	00000
00000000	Angel-Backed	Boston, MA	0	00.000	0000000000	00.000
00000	Formerly VC-backed	Ness Ziona, Israel	000	00000	00000000000	00000
00000 00000000000	Formerly VC-backed	Cambridge, MA	00	00000	000000000	00000

You’re viewing 5 of 16 competitors. Get the full list »

Pherecydes Pharma Executive Team (7)

Name	Title	Board Seat	Contact Info
Guy-Charles de La Horie	Chief Executive Officer
Philippe Rousseau	Chief Operating Officer & Chief Financial Officer
Patrick Champion-Arnaud Ph.D	Chief Marketing Officer
Cindy Fevre Ph.D	Chief Scientific Officer

You’re viewing 4 of 7 executive team members. Get the full list »

Pherecydes Pharma Board Members (5)

Name	Representing	Role
Claire Poulard	Omnes Capital	Supervisory Board Member
Didier Hoch	Self	Chairman
Franck Lescure Ph.D	Auriga Partners (Paris)	Supervisory Board Member
Leila Guerlain Nicolas	GO Capital (France)	Supervisory Board Member